Dec 22, 2016
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression
A. v. Mässenhausen, J. Brägelmann, H. Billig, B. Thewes , A. Queisser, W. Vogel, G. Kristiansen, A. Schröck, F. Bootz, P. Brossart, J. Kirfel, S. Perner , International Journal of Molecular Sciences , DOI: 10.3390/ijms18010007
Head and neck squamous cell carcinoma (HNSCC) remains a clinical challenge and identification of novel therapeutic targets is necessary. The receptor tyrosine kinase AXL has been implicated in several tumor entities and a selective AXL small molecule inhibitor (BGB324) is currently being tested in clinical trials for patients suffering from...
Dec 15, 2016
Stroma in pancreatic cancer: Automated quantification and its prognostic significance
R. J. Torphy, R. Naim, B. Midkiff, K. Volmar, E. Collisson, J. J. Yeh , Cancer Research , DOI: 10.1158/1538-7445.PANCA16-B80
Tumor stroma (TS) is a cardinal component of pancreatic ductal adenocarcinoma (PDAC); it comprises 60 to 90% of tumor volume and is an emerging treatment target. There are conflicting reports of the role that TS plays in disease progression and its prognostic significance. The objective of this study was to...
Dec 13, 2016
MATE2 Expression Is Associated with Cancer Cell Response to Metformin
S. Chowdhury, E. Yung, M. Pintilie, H. Muaddi, S. Chaib, M. Yeung, M. Fusciello, J. Sykes, B. Pitcher, A. Hagenkort, T. McKee, R. Vellanki, E. Chen, R. G. Bristow, B. G. Wouters, M. Koritzinsky , PLoS ONE , DOI: 10.1371/journal.pone.0165214
Background: There is great interest in repurposing the commonly prescribed anti-diabetic drug metformin for cancer therapy. Intracellular uptake and retention of metformin is affected by the expression of organic cation transporters (OCT) 1–3 and by multidrug and toxic compound extrusion (MATE) 1–2. Inside cells, metformin inhibits mitochondrial function, which leads...
Dec 10, 2016
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling
A. Offermann, I. Vlasic, I. Syring, W. Vogel, C. Ruiz, T. Zellweger, C. A. Rentsch, S. Hagedorn, J. Behrends, M. Nowak, A. Merseburger, L. Bubendorf, J. Kirfel, S. Duensing, Z. Shaikhibrahim, Sven Perner , Oncotarget , DOI: 10.18632/oncotarget.13860
Androgen deprivation therapy (ADT) is the main therapeutic option for advanced prostate cancer (PCa). After initial regression, most tumors develop into castration-resistant PCa (CRPC). Previously, we found the Mediator complex subunit MED15 to be overexpressed in CRPC and to correlate with clinical outcome. Therefore, we investigated whether MED15 is implicated...
Dec 9, 2016
Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications
R. Saito, H. Abe, A. Kunita, H. Yamashita, Y. Seto, M. Fukayama , Modern Pathology , DOI. 10.1038/modpathol.2016.202
Cancer cells use PD-L1 to evade antitumor immunity through interaction with programmed cell death protein 1 (PD-1) on T cells. Recent whole-genome sequence studies revealed frequent gene amplification of PD-L1 in Epstein–Barr virus-associated gastric cancer (EBVaGC). To investigate the significance of PD-L1 in cancer cells and their microenvironment in EBVaGC,...